文献速递产科母胎医学

妊娠合并母体心肌病围产结局的系统评价与Meta分析

Perinatal outcomes in pregnancies complicated by maternal cardiomyopathy: a systematic review and meta-analysis.
PubMed 文献 · Am J Obstet Gynecol · 2022-09-20

该系统评价与Meta分析纳入13项观察性研究(共2,291,024次妊娠),评估妊娠合并母体心肌病的围产结局。与无心脏病孕妇相比,心肌病孕妇的胎儿死产和新生儿死亡风险显著升高;与其他心脏病孕妇相比,死产、新生儿死亡、早产和小于胎龄儿风险也显著升高。作者建议计划妊娠的心肌病女性接受详细咨询,并由经验丰富的多学科团队管理。

要点

  • 心肌病孕妇较无心脏病孕妇死产风险显著升高(OR 20.82)。
  • 心肌病孕妇较其他心脏病孕妇早产风险显著升高(OR 2.21)。
  • 心肌病孕妇较其他心脏病孕妇小于胎龄儿风险显著升高(OR 2.97)。

核心结论

  • 与无心脏病和其他形式心脏病孕妇相比,妊娠合并母体心肌病的不良围产结局风险升高。
  • 计划妊娠的心肌病女性应接受详细风险咨询,并由经验丰富的多学科团队管理,提供密切胎儿监测和新生儿专业支持。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Ovid Embase、Ovid MEDLINE、Cochrane Library和ClinicalTrials.gov从建库至2022年8月25日。
  • 纳入报告预设围产结局的观察性队列、病例对照和病例队列研究,比较心肌病孕妇(任何亚型)与无已知心脏病或非心肌病心脏病孕妇。
  • 最终纳入13项研究,代表2,291,024次妊娠。

主要发现

  • 心肌病孕妇的新生儿死产风险较无心脏病孕妇升高(OR 20.82,95%CI 6.68-64.95,I²不可用,P<.00001)。
  • 心肌病孕妇的新生儿死亡风险较无心脏病孕妇升高(OR 6.75,95%CI 3.54-12.89,I²=0%,P<.00001)。
  • 心肌病孕妇的死产风险较其他心脏病孕妇升高(OR 3.75,95%CI 1.86-7.59,I²=0%,P=.0002)。
  • 心肌病孕妇的新生儿死亡风险较其他心脏病孕妇升高(OR 2.42,95%CI 1.39-4.21,I²=0%,P=.002)。
  • 心肌病孕妇的早产风险(OR 2.21,95%CI 1.31-3.73,I²=77%,P=.003)和小于胎龄儿风险(OR 2.97,95%CI 2.38-3.70,I²=47%,P<.00001)较其他心脏病孕妇升高。

临床怎么用

  • 作者建议计划妊娠的心肌病女性接受关于这些风险的详细咨询。
  • 作者建议妊娠应由经验丰富的多学科团队管理,提供密切胎儿监测和新生儿专业支持。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to systematically assess perinatal outcomes of pregnancies complicated by maternal cardiomyopathy. DATA SOURCES: PubMed, Ovid Embase, Ovid MEDLINE, the Cochrane Library, and ClinicalTrials.gov were systematically searched from inception to August 25, 2022. STUDY ELIGIBILITY CRITERIA: Observational cohort, case-control, and case-cohort studies in human populations were included if they reported predefined perinatal outcomes in pregnant women with cardiomyopathy (any subtype) and an appropriate control population (either pregnant women with no known cardiac disease or pregnant women with noncardiomyopathy cardiac disease). METHODS: Of note, 2 reviewers independently assessed the articles for eligibility and risk of bias, and conflicts were resolved by a third reviewer. Data were extracted and synthesized according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Meta-analysis of Observational Studies in Epidemiology guidelines. RESULTS: Here, 13 studies (representing 2,291,024 pregnancies) were eligible for inclusion. Perinatal death was more likely in neonates born to women with cardiomyopathy than in (1) neonates born to women with no cardiac disease (stillbirth: odds ratio, 20.82; 95% confidence interval, 6.68-64.95; I2 = not available; P<.00001; neonatal mortality: odds ratio, 6.75; 95% confidence interval, 3.54-12.89; I2=0%; P<.00001) and (2) neonates born to women with other forms of cardiac disease (stillbirth: odds ratio, 3.75; 95% confidence interval, 1.86-7.59; I2=0%; P=.0002; neonatal mortality: odds ratio, 2.42; 95% confidence interval, 1.39-4.21; I2=0%; P=.002). Pregnancies affected by maternal cardiomyopathy were significantly more likely to result in preterm birth (odds ratio, 2.21; 95% confidence interval, 1.31-3.73; I2=77%; P=.003) and small-for-gestational-age neonates (odds ratio, 2.97; 95% confidence interval, 2.38-3.70; I2=47%; P<.00001), both major causes of short- and long-term morbidities, than pregnancies affected by other forms of cardiac disease. CONCLUSION: There was an increased likelihood of adverse perinatal outcomes in pregnancies affected by maternal cardiomyopathy compared with both pregnancies affected by noncardiomyopathy cardiac disease and pregnancies without cardiac disease. Women with cardiomyopathy who plan to get pregnant should receive detailed counseling regarding these risks and have their pregnancies managed by experienced multidisciplinary teams that can provide close fetal monitoring and neonatology expertise.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Eggleton EJ, McMurrugh KJ, Aiken CE, et al. Perinatal outcomes in pregnancies complicated by maternal cardiomyopathy: a systematic review and meta-analysis. Am J Obstet Gynecol. 2022. PMID: 36150520. doi:10.1016/j.ajog.2022.09.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。